Endo International PLC Forecasted to Earn Q4 2016 Earnings of $1.80 Per Share (ENDP)
Endo International PLC (NASDAQ:ENDP) – Stock analysts at William Blair dropped their Q4 2016 earnings estimates for shares of Endo International PLC in a research note issued on Wednesday. William Blair analyst T. Lugo now expects that the firm will post earnings of $1.80 per share for the quarter, down from their prior forecast of $1.81. William Blair also issued estimates for Endo International PLC’s FY2017 earnings at $4.86 EPS.
A number of other analysts also recently weighed in on ENDP. Oppenheimer Holdings Inc. restated a “hold” rating on shares of Endo International PLC in a report on Tuesday. BMO Capital Markets reiterated a “hold” rating on shares of Endo International PLC in a report on Friday. Piper Jaffray Cos. reiterated a “neutral” rating and set a $19.00 price target on shares of Endo International PLC in a report on Tuesday, September 27th. Royal Bank Of Canada cut their price target on shares of Endo International PLC from $26.00 to $21.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, Susquehanna upgraded shares of Endo International PLC from a “neutral” rating to a “positive” rating and set a $20.00 price target on the stock in a report on Thursday. One analyst has rated the stock with a sell rating, nine have issued a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $33.52.
Endo International PLC (NASDAQ:ENDP) opened at 17.58 on Thursday. The firm’s 50 day moving average is $19.61 and its 200-day moving average is $19.06. The company’s market cap is $3.92 billion. Endo International PLC has a 52 week low of $12.56 and a 52 week high of $63.71.
Endo International PLC (NASDAQ:ENDP) last announced its earnings results on Tuesday, November 8th. The company reported $1.01 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.81 by $0.20. Endo International PLC had a negative net margin of 3.32% and a positive return on equity of 15.95%. The business earned $894.30 million during the quarter, compared to the consensus estimate of $862.47 million. During the same quarter last year, the firm earned $1.02 earnings per share. The business’s revenue for the quarter was up 18.6% on a year-over-year basis.
Hedge funds have recently added to or reduced their stakes in the company. State Street Corp raised its stake in Endo International PLC by 9.3% in the second quarter. State Street Corp now owns 9,430,866 shares of the company’s stock worth $147,021,000 after buying an additional 805,101 shares during the last quarter. Geode Capital Management LLC raised its stake in Endo International PLC by 0.9% in the first quarter. Geode Capital Management LLC now owns 1,759,167 shares of the company’s stock worth $49,422,000 after buying an additional 15,173 shares during the last quarter. RS Investment Management Co. LLC raised its stake in Endo International PLC by 0.4% in the second quarter. RS Investment Management Co. LLC now owns 1,374,185 shares of the company’s stock worth $21,424,000 after buying an additional 6,132 shares during the last quarter. Heartland Advisors Inc. acquired a new stake in Endo International PLC during the second quarter worth $15,627,000. Finally, TIAA CREF Investment Management LLC raised its stake in Endo International PLC by 27.4% in the third quarter. TIAA CREF Investment Management LLC now owns 955,182 shares of the company’s stock worth $19,247,000 after buying an additional 205,522 shares during the last quarter. Hedge funds and other institutional investors own 96.61% of the company’s stock.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.